Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CVAC CureVac	$5.37	$5.43	$2.37 ▼ $5.72	$1.20B	2.53	636,357 shs	321,215 shs
MRNA Moderna	$24.09 -1.6%	$29.09	$23.15 ▼ $79.96	$9.37B	1.93	9.04 million shs	8.27 million shs
OCGN Ocugen	$1.02 -2.9%	$1.03	$0.52 ▼ $1.33	$298.15M	4.16	2.04 million shs	1.78 million shs
PFE Pfizer	$24.74 +0.6%	$24.79	$20.92 ▼ $30.43	$140.65B	0.55	43.00 million shs	37.00 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CVAC CureVac	0.00%	-1.29%	-0.74%	+15.98%	+71.02%
MRNA Moderna	0.00%	-11.17%	-12.72%	-10.94%	-68.88%
OCGN Ocugen	0.00%	+0.99%	+2.66%	+21.83%	-21.54%
PFE Pfizer	0.00%	-4.21%	+5.32%	+5.52%	-14.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CVAC CureVac	4.4161 of 5 stars	3.1	5.0	0.0	4.9	3.5	0.0	1.3
MRNA Moderna	4.5111 of 5 stars	4.0	2.0	0.0	4.6	2.2	2.5	1.3
OCGN Ocugen	1.5431 of 5 stars	3.5	2.0	0.0	0.0	2.7	0.0	0.0
PFE Pfizer	4.7829 of 5 stars	2.2	3.0	4.2	4.5	2.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CVAC CureVac	2.20	Hold	$6.83	27.25% Upside
MRNA Moderna	2.04	Hold	$42.88	78.01% Upside
OCGN Ocugen	3.00	Buy	$6.00	488.24% Upside
PFE Pfizer	2.39	Hold	$28.12	13.66% Upside

Current Analyst Ratings Breakdown

Latest OCGN, MRNA, PFE, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	MRNA Moderna	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$18.00 ➝ $15.00
8/6/2025	PFE Pfizer	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$25.00 ➝ $26.00
8/6/2025	PFE Pfizer	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$32.00 ➝ $33.00
8/6/2025	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$27.00 ➝ $28.00
8/4/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $31.00
8/4/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/1/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$32.00
8/1/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$26.00
8/1/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
8/1/2025	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$32.00
7/22/2025	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$26.00 ➝ $25.00

(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CVAC CureVac	$510.51M	2.36	$0.87 per share	6.15	$3.36 per share	1.60
MRNA Moderna	$3.06B	3.07	N/A	N/A	$28.33 per share	0.85
OCGN Ocugen	$4.75M	62.72	N/A	N/A	$0.10 per share	10.20
PFE Pfizer	$63.63B	2.21	$4.36 per share	5.67	$15.62 per share	1.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CVAC CureVac	$175.50M	$0.96	5.59	N/A	N/A	38.21%	29.57%	25.41%	11/11/2025 (Estimated)
MRNA Moderna	-$3.56B	-$7.53	N/A	N/A	N/A	-94.31%	-25.96%	-20.09%	11/6/2025 (Estimated)
OCGN Ocugen	-$54.05M	-$0.20	N/A	N/A	N/A	-1,197.71%	-255.25%	-86.79%	11/13/2025 (Estimated)
PFE Pfizer	$8.03B	$1.88	13.16	8.16	0.88	16.84%	21.42%	9.12%	11/4/2025 (Estimated)

Latest OCGN, MRNA, PFE, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	CVAC CureVac	-$0.15	-$0.30	-$0.15	-$0.30	$4.27 million	$1.41 million
8/5/2025	Q2 2025	PFE Pfizer	$0.58	$0.78	+$0.20	$0.51	$13.43 billion	$14.65 billion
8/1/2025	Q2 2025	MRNA Moderna	-$2.99	-$2.13	+$0.86	-$2.13	$116.26 million	$142.00 million
8/1/2025	Q2 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	$0.35 million	$1.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.95%	N/A	91.49%	16 Years

Latest OCGN, MRNA, PFE, and CVAC Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/25/2025	PFE Pfizer	quarterly	$0.43	7.08%	7/25/2025	7/25/2025	9/2/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CVAC CureVac	0.05	6.17	6.16
MRNA Moderna	N/A	3.93	3.77
OCGN Ocugen	9.18	1.83	1.83
PFE Pfizer	0.65	1.16	0.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CVAC CureVac	17.26%
MRNA Moderna	75.33%
OCGN Ocugen	10.27%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
CVAC CureVac	2.15%
MRNA Moderna	11.00%
OCGN Ocugen	4.42%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CVAC CureVac	880	224.34 million	N/A	Optionable
MRNA Moderna	5,800	389.08 million	346.28 million	Optionable
OCGN Ocugen	80	292.31 million	279.77 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

OCGN, MRNA, PFE, and CVAC Headlines

Recent News About These Companies

Pfizer's Golden Cross Signals Strength: How to Play the Stock

3 hours ago | zacks.com

Trump tells drugmakers to 'justify the success' of Covid meds after FDA limits vaccine approval

5 hours ago | cnbc.com

Armistice Capital LLC Acquires Shares of 211,740 Pfizer Inc. $PFE

September 1 at 8:33 AM | marketbeat.com

Baird Financial Group Inc. Sells 188,043 Shares of Pfizer Inc. $PFE

September 1 at 6:41 AM | marketbeat.com

Pfizer's 7% Dividend: Income Gem or Value Trap?

September 1 at 6:30 AM | fool.com

Pfizer's 7% Dividend: Income Gem or Value Trap?

September 1 at 6:00 AM | fool.com

Healthcare Is Sickly, But These Yields up to 7% May Still Have a Pulse

...

August 31 at 10:09 PM | marketbeat.com

FRG Family Wealth Advisors LLC Reduces Stake in Pfizer Inc. $PFE

August 31 at 7:36 AM | marketbeat.com

Centric Wealth Management Acquires 20,164 Shares of Pfizer Inc. $PFE

August 31 at 7:13 AM | marketbeat.com

3 No-Brainer Stocks to Buy Right Now

August 31 at 6:45 AM | fool.com

Magnetar Financial LLC Acquires New Position in Pfizer Inc. $PFE

August 31 at 5:57 AM | marketbeat.com

Pfizer Inc. $PFE Shares Sold by The Manufacturers Life Insurance Company

August 31 at 5:44 AM | marketbeat.com

Canada Pension Plan Investment Board Sells 2,484,464 Shares of Pfizer Inc. $PFE

August 31 at 5:36 AM | marketbeat.com

Landscape Capital Management L.L.C. Purchases 11,469 Shares of Pfizer Inc. $PFE

August 31 at 5:18 AM | marketbeat.com

Pfizer (PFE) Announces FDA Approval of sBLA for Pfizer-BioNTech COVID-19 Vaccine

August 31 at 2:17 AM | ca.finance.yahoo.com

4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer

August 30 at 9:11 AM | fool.com

4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer

August 30 at 8:45 AM | fool.com

Evergreen Capital Management LLC Has $10.58 Million Holdings in Pfizer Inc. $PFE

August 30 at 7:25 AM | marketbeat.com

Pfizer Inc. $PFE Shares Bought by Te Ahumairangi Investment Management Ltd

August 30 at 6:41 AM | marketbeat.com

Better High-Yielding Dividend Stock: Realty Income vs. Pfizer

August 30 at 6:11 AM | fool.com

Itau Unibanco Holding S.A. Decreases Stake in Pfizer Inc. $PFE

August 30 at 6:00 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OCGN, MRNA, PFE, and CVAC Company Descriptions

CureVac NASDAQ:CVAC

$5.37 0.00 (0.00%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$5.38 +0.00 (+0.09%)

As of 08/29/2025 06:27 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Moderna NASDAQ:MRNA

$24.09 -0.38 (-1.55%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$24.16 +0.07 (+0.29%)

As of 08/29/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Ocugen NASDAQ:OCGN

$1.02 -0.03 (-2.86%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$1.03 +0.01 (+0.59%)

As of 08/29/2025 07:55 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Pfizer NYSE:PFE

$24.74 +0.14 (+0.57%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$24.78 +0.04 (+0.15%)

As of 08/29/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time